Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C ...

Detailed price information for Atea Pharmaceuticals Inc (AVIR-Q) from The Globe and Mail including charting and trades.